PolyPid Ltd. (PYPD): Price and Financial Metrics
GET POWR RATINGS... FREE!
PYPD Stock Price Chart Interactive Chart >
PYPD Price/Volume Stats
| Current price | $0.79 | 52-week high | $7.75 |
| Prev. close | $0.78 | 52-week low | $0.65 |
| Day low | $0.73 | Volume | 14,522 |
| Day high | $0.79 | Avg. volume | 294,262 |
| 50-day MA | $0.95 | Dividend yield | N/A |
| 200-day MA | $3.86 | Market Cap | 15.45M |
PolyPid Ltd. (PYPD) Company Bio
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.
Latest PYPD News From Around the Web
Below are the latest news stories about POLYPID LTD that investors may wish to consider to help them evaluate PYPD as an investment opportunity.
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma AssociationD-PLEX₁₀₀ Infection Prevention Efficacy in Patients with Increased Risk for Surgical Wound Infections Including Multi-Drug Resistant Organisms (MDROs) will be Presented During a Podium PresentationPETACH TIKVA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX100 will be highlighted in a podium presentation at the first trienn |
PolyPid (PYPD) Gets a Buy from JMP SecuritiesE ratio of -0.30. |
PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsCompany Intends to Meet with U.S. and EU Regulatory Authorities to Discuss Data from SHIELD I Phase 3 Study and Regulatory Pathway for D-PLEX100 in First Quarter of 2023 Implemented a Cost Reduction Plan, Including a 20% Decrease in Headcount Across All Departments Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (PolyPid or the Company), a late-stage biopharma company aiming to improve surgical outcomes, today |
PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 9, 2022. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business ope |
PolyPid Announces Cost Reduction PlanReduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 2023 PolyPid Intends to Discuss Regulatory Pathway for D-PLEX100 for Prevention of Surgical Site Infections in Abdominal Surgery with U.S. and EU Regulatory Authorities in Q1 2023 PETACH TIKVA, Israel, Oct. 20, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a cost reduction pl |
PYPD Price Returns
| 1-mo | -14.13% |
| 3-mo | -85.34% |
| 6-mo | -85.12% |
| 1-year | -88.38% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -86.24% |
| 2021 | -42.02% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...